JP4883753B2 - 医薬 - Google Patents
医薬 Download PDFInfo
- Publication number
- JP4883753B2 JP4883753B2 JP2005258186A JP2005258186A JP4883753B2 JP 4883753 B2 JP4883753 B2 JP 4883753B2 JP 2005258186 A JP2005258186 A JP 2005258186A JP 2005258186 A JP2005258186 A JP 2005258186A JP 4883753 B2 JP4883753 B2 JP 4883753B2
- Authority
- JP
- Japan
- Prior art keywords
- group
- cancer
- carbon atoms
- alicyclic hydrocarbon
- general formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
で表わされるホスフィンオキシド基で置換された芳香族化合物を用いた発光素子(特許文献6参照)、ポリイソプレニルモノホスフェート化合物を活性成分とした制癌剤(特許文献7参照)などが知られている。
で表わされるオキソリン化合物を有効成分として含有する医薬であって、前記nが1のとき、一般式
で表わされるオキソリン化合物であり、前記nが0のとき、一般式
で表わされるオキソリン化合物である、癌細胞増殖抑制剤である医薬を提供するものである。
表1に示す化合物について、ヒト白血病U937、ヒト結腸癌HT29、マウス筋繊維癌S180及びマウス正常線維芽細胞株NIH3T3細胞を用いて癌細胞増殖抑制効果を試験した。
これらの結果を表1に示した。
表2に示す化合物について実施例1〜11と同様にして、ヒト白血病U937、ヒト結腸癌HT29、マウス筋繊維癌S180及びマウス正常線維芽細胞株NIH3T3細胞を用いて癌細胞増殖抑制効果を試験した。
その結果を表2に示す。なお、比較のためにシスプラチンを用いた場合の結果も併記した。
Claims (3)
- 一般式
で表わされるオキソリン化合物を有効成分として含有する医薬であって、
前記nが1のとき、一般式
で表わされるオキソリン化合物であり、
前記nが0のとき、一般式
で表わされるオキソリン化合物である、
癌細胞増殖抑制剤である医薬。 - 癌細胞が固形癌細胞又はリンパ腫細胞である請求項1記載の医薬。
- 癌細胞が皮膚癌、膀胱癌、乳癌、子宮癌、卵巣癌、前立腺癌、肺癌、大腸癌、膵臓癌、腎臓癌又は胃癌の細胞である請求項1又は2記載の医薬。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005258186A JP4883753B2 (ja) | 2005-09-06 | 2005-09-06 | 医薬 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005258186A JP4883753B2 (ja) | 2005-09-06 | 2005-09-06 | 医薬 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2007070278A JP2007070278A (ja) | 2007-03-22 |
JP4883753B2 true JP4883753B2 (ja) | 2012-02-22 |
Family
ID=37932041
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2005258186A Expired - Fee Related JP4883753B2 (ja) | 2005-09-06 | 2005-09-06 | 医薬 |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP4883753B2 (ja) |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5543396A (en) * | 1994-04-28 | 1996-08-06 | Georgia Tech Research Corp. | Proline phosphonate derivatives |
JP3662501B2 (ja) * | 2001-02-14 | 2005-06-22 | 独立行政法人科学技術振興機構 | アルケニルホスフィンオキシド類の製造方法 |
US7893072B2 (en) * | 2003-07-02 | 2011-02-22 | Genentech, Inc. | Trp-p8 active compounds and therapeutic treatment methods |
-
2005
- 2005-09-06 JP JP2005258186A patent/JP4883753B2/ja not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
JP2007070278A (ja) | 2007-03-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2002223302B2 (en) | Treatment of statin side effects | |
AU774362B2 (en) | Lipoic acid derivatives and their use in treatment of disease | |
EP3521294A1 (en) | Pharmaceutical compounds for use in the therapy of clostridium difficile infection | |
AU2002223302A1 (en) | Treatment of statin side effects | |
US8507710B2 (en) | Use of perifosine in combination with antimetabolites for the treatment of benign and malignant oncoses in humans and mammals | |
WO1999042099A1 (en) | Low molecular weight compounds administered together with anti-cancer agents to treat cancer and pharmaceutical compositions thereof | |
WO2016181312A1 (en) | Polycyclic epoxides and compositions thereof with anti-cancer activities | |
Mironov et al. | Dimephosphone analogs: a pharmacological aspect | |
WO2020263893A1 (en) | Cannabinoid conjugate molecules | |
CA2191850C (en) | Cancerous metastasis inhibitor | |
CN102627685B (zh) | 一氧化氮供体型谷胱甘肽类化合物、其制备方法及医药用途 | |
CN101326191B (zh) | 膦过渡金属配合物、其制造方法和含有该配合物的抗癌剂 | |
JPH0296523A (ja) | 白金化学療法生成物 | |
JP4883753B2 (ja) | 医薬 | |
JP5553275B2 (ja) | 金属錯体およびこれを有効成分として含有する抗がん剤 | |
JP4963547B2 (ja) | オキソリン化合物を有効成分とする医薬 | |
RU2240793C1 (ru) | Противоопухолевое средство | |
CN100582101C (zh) | 抗肿瘤剂 | |
US8436044B2 (en) | Pharmaceutical composition or combination drug | |
US3169091A (en) | Process for inhibiting tumors with substituted pyrazoles | |
EP1299400B1 (en) | Novel cytotoxic compounds and their use | |
GB1594840A (en) | 5-fluorouracil derivatives and pharmaceutical compositions containing the same | |
US20230381083A1 (en) | Phytic Acid Ester Derivative | |
Yount et al. | A novel camptothecin analog with enhanced antitumor activity | |
JPH0211513A (ja) | 制癌剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20080305 |
|
RD01 | Notification of change of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7421 Effective date: 20090608 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110722 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110920 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20111118 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20111205 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20141216 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
LAPS | Cancellation because of no payment of annual fees |